Evidence map›Paper›PMID 30323092›Full record

ArticleJournal of the National Comprehensive Cancer Network : JNCCN2018

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Crystal S Denlinger, Tara Sanft, K Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King and 24 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881940 (Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab), which is not on this map. Cited by 108 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 3 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06881940 nanot yet recruitingnot on this mapstarted 2025, after this paper: background citation

Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2025 to 2029Enrolled284ConditionsCancer Therapy-Related Cardiac DysfunctionArmsRehabilitation Program, No Rehabilitation Program
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 3 syntheses or guidelines pooled it, 193 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Impact of TauroLockEuropean journal of medical research · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.The New England journal of medicine · 2019
    Trial
  11. Expression of AR-V7 and ARvClinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Observational

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 2 institutions in 2 countries.

Crystal S Denlinger
Tara Sanft
K Scott Baker
Gregory Broderick
Wendy Demark-Wahnefried
Debra L Friedman
Mindy Goldman
Melissa Hudson
Nazanin Khakpour
Allison King
Divya Koura
Robin M Lally
Terry S Langbaum
Allison L McDonough
Michelle Melisko
Jose G Montoya
Kathi Mooney
Javid J Moslehi
Tracey O'Connor
Linda Overholser
Electra D Paskett
Jeffrey Peppercorn
William Pirl
M Alma Rodriguez
Kathryn J Ruddy
Paula Silverman
Sophia Smith
Karen L Syrjala
Amye Tevaarwerk
Susan G Urba
Mark T Wakabayashi
Phyllis Zee
Nicole R McMillian
Deborah A Freedman-Cass
Barnes-Jewish Hospital · USGoldman Sachs (United States) · US

Funding

Integrating health informatics in a scalable stepped care self-management program for survivors after hematopoietic cell transplantationR01CA215134 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BAKER, KEVIN S, MAJHAIL, NAVNEET S. · 2017 to 2022
$3.6M
NCI NIH HHS R01 CA215134
6 · The paper itself

Abstract

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.

Indexed as

Cancer SurvivorsSurvivorshipAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalBacterial InfectionsCardiotoxicityHumansImmunocompromised HostLymphedemaMass ScreeningMedical OncologyNeoplasmsRisk AssessmentSocieties, MedicalUnited StatesAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Agents, Immunological

Identifiers

PMID30323092
PMCPMC6438378
OpenAlexW2896465321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.